STATE AND FEDERAL PHARMACY INTELLIGENCE RESOURCE

Blog

  • Affordable Care Act Repeal and Replacement in 2017?

    Feb 10, 2017

    by Lauren Fuller

    President Donald J. Trump and the Republican Congress repeatedly promised to expeditiously repeal the Patient Protection and Affordable Care Act (“Affordable Care Act” or “ObamaCare”). The Republicans in Congress tried multiple times during the last six years to repeal the …

  • Interchangeable Biosimilars – State Substitution Requirements Update

    Feb 6, 2017

    by Lauren Fuller

    Question:  Are you aware of the 26 states & territories that passed substitution requirements on interchangeable biosimilars? Or how these are affected by FDA’s draft guidance entitled, Considerations for Demonstrating Interchangeability with a Reference Product? In January 2017, the Food …

  • UPDATE: Naloxone and Opioid Antagonist Prescription Status in the States

    Feb 2, 2017

    by SAFPhIR Team

    2015 was a record year for deaths linked to opioids. 33,000 deaths in one year. And the government has taken note. We’re already seeing unprecedented numbers of legislative and regulatory actions being taken at State and Federal levels with new …

  • Drug Pricing Transparency: How And Where You’ll Be Impacted

    Dec 13, 2016

    by SAFPhIR Team

    On the tailwind of several high-profile drug pricing increases, and resulting media firestorms, we’re seeing intense focus on pharmaceutical pricing practices. States and the federal government are both reacting strongly — 2016 saw a record number of policy initiatives aimed …

  • Repeal and Replace? Affordable Care Act and the Impending Avalanche of Change

    Nov 12, 2016

    by Lauren Fuller

    The 2016 elections resulted in the selection of a Republican President and Congress, taking the reins of the federal government in 2017.  The President-elect Donald J. Trump repeatedly promised to repeal the Patient Protection and Affordable Care Act (“Affordable Care …

  • Introductory Offer

    Oct 1, 2016

    by SAFPhIR Team

    We are offering free limited access to our online subscription-based service, which combines new law and regulatory activity with expert policy analysis and high–level guidance. To make it easy for you, we have identified topics that we think would be …

  • UPDATE: Interchangeable Biosimilars – State Substitution Requirements

    Aug 9, 2016

    by SAFPhIR Team

    Question:  Do you know the latest on five new states that passed substitution requirements on interchangeable biosimilars? Although the Food and Drug Administration (FDA) stated its plans to issue guidance on interchangeability of biosimilars this year, it has not done so …

Login